JP2012529281A - 抗ＥｐＣＡＭ抗体 - Google Patents

抗ＥｐＣＡＭ抗体 Download PDF

Info

Publication number
JP2012529281A
JP2012529281A JP2012514538A JP2012514538A JP2012529281A JP 2012529281 A JP2012529281 A JP 2012529281A JP 2012514538 A JP2012514538 A JP 2012514538A JP 2012514538 A JP2012514538 A JP 2012514538A JP 2012529281 A JP2012529281 A JP 2012529281A
Authority
JP
Japan
Prior art keywords
antibody
seq
sequence
epcam
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012514538A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012529281A5 (https=
Inventor
ガンナーソン， ラヴィニア ディアナ シコータス
ディドゥリク パウス，
ジェニー マルガレタ カールソン，
レンコ アルバート グリエプ，
セルゲジュ ミチャイロヴィク キプリジャノヴ，
Original Assignee
アフィテック リサーチ エイエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アフィテック リサーチ エイエス filed Critical アフィテック リサーチ エイエス
Publication of JP2012529281A publication Critical patent/JP2012529281A/ja
Publication of JP2012529281A5 publication Critical patent/JP2012529281A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2012514538A 2009-06-09 2010-06-09 抗ＥｐＣＡＭ抗体 Pending JP2012529281A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18538709P 2009-06-09 2009-06-09
GBGB0909904.5A GB0909904D0 (en) 2009-06-09 2009-06-09 Product
GB0909904.5 2009-06-09
US61/185,387 2009-06-09
PCT/GB2010/050969 WO2010142990A1 (en) 2009-06-09 2010-06-09 ANTI-EpCAM ANTIBODIES

Publications (2)

Publication Number Publication Date
JP2012529281A true JP2012529281A (ja) 2012-11-22
JP2012529281A5 JP2012529281A5 (https=) 2013-07-25

Family

ID=40937119

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012514538A Pending JP2012529281A (ja) 2009-06-09 2010-06-09 抗ＥｐＣＡＭ抗体

Country Status (8)

Country Link
US (1) US8637017B2 (https=)
EP (1) EP2440580A1 (https=)
JP (1) JP2012529281A (https=)
CN (1) CN102549017A (https=)
BR (1) BRPI1011005A2 (https=)
EA (1) EA201171463A1 (https=)
GB (1) GB0909904D0 (https=)
WO (1) WO2010142990A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510755A (ja) * 2013-03-06 2016-04-11 メリマック ファーマシューティカルズ インコーポレーティッド 抗Ｃ−ＭＥＴタンデムＦｃ二重特異性抗体
JP2020515262A (ja) * 2017-03-29 2020-05-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
JP2022506072A (ja) * 2018-10-26 2022-01-17 イミュノジェン， インコーポレイテッド ＥｐＣＡＭ抗体、活性化可能抗体、および免疫複合体、ならびにそれらの使用

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2524124C (en) 2003-04-30 2014-03-25 Uwe Zangemeister-Wittke Methods for treating cancer using an immunotoxin
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MY162056A (en) 2006-10-12 2017-05-31 Univ Tokyo Diagnosis and treatment of cancer using anti -ereg antibody
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
TWI593705B (zh) * 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
TWI485161B (zh) * 2012-03-02 2015-05-21 中央研究院 抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法
PL2897978T3 (pl) * 2012-09-19 2017-08-31 Abbvie Biotherapeutics Inc. Sposoby identyfikacji przeciwciał o obniżonej immunogenności
CN103387989B (zh) * 2012-09-24 2016-05-18 厦门大学 上皮细胞粘附分子的核酸适体EpCAM D及其制备方法
US20140248292A1 (en) * 2013-03-04 2014-09-04 Oslo Universitetssykehus Hf Compositions and methods for treating cancer
CA2909153A1 (en) * 2013-04-12 2014-10-16 Viventia Bio Inc. Compositions and methods for detection and treatment of hepatocellular carcinoma
CN103275226B (zh) * 2013-06-09 2017-08-29 中国科学技术大学 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用
MX2015017852A (es) * 2013-06-24 2016-08-11 Chugai Pharmaceutical Co Ltd Agente terapeutico que comprende el anticuerpo anti-epirregulina humanizado con ingrediente activo contra el carcinoma de pulmon de celulas no pequeñas excluyendo el adenocarcinoma.
WO2015048901A1 (en) 2013-10-02 2015-04-09 Viventia Bio Inc. Anti-epcam antibodies and methods of use
US10583198B2 (en) 2015-03-12 2020-03-10 Viventia Bio Inc. Dosing strategies for targeting EPCAM positive bladder cancer
EP3268040A4 (en) 2015-03-12 2018-09-12 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer
EP3770171A1 (en) * 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
US11098131B2 (en) 2015-07-31 2021-08-24 Sutro Biopharma, Inc. Anti-EpCAM antibodies, compositions comprising anti-EpCAM antibodies and methods of making and using anti-EpCAM antibodies
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
US20190262397A1 (en) 2016-07-26 2019-08-29 Tessa Therapeutics Pte. Ltd. Chimeric antigen receptor
CN107814846A (zh) * 2016-11-14 2018-03-20 杭州华得森生物技术有限公司 针对EpCAM和Cytokeratin5的特异性抗体及其制备方法
SG10202102502VA (en) * 2017-09-07 2021-04-29 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and a tumor-associated antigen
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
EA202091887A1 (ru) 2018-02-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
CN108484771A (zh) * 2018-04-24 2018-09-04 南京市妇幼保健院 EpCAM单域抗体G7
JPWO2019244973A1 (ja) 2018-06-20 2021-07-08 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CA3120800A1 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
WO2020216210A1 (zh) * 2019-04-22 2020-10-29 江苏恒瑞医药股份有限公司 抗EpCAM抗体及其应用
CN110950959B (zh) * 2020-02-25 2020-07-03 和铂医药(上海)有限责任公司 靶向EpCAM的抗体及其制备和应用
CN115010811B (zh) * 2020-03-11 2024-04-19 南京融捷康生物科技有限公司 可特异性结合EpCAM的单域抗体及其应用
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
WO2021231237A2 (en) * 2020-05-11 2021-11-18 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof
CN112359052B (zh) * 2020-08-20 2023-01-03 山东兴瑞生物科技有限公司 抗EpCAM嵌合抗原受体的编码基因、制备方法、具有该基因的质粒、免疫细胞及其应用
EP4274605A4 (en) * 2021-01-11 2025-03-12 TigaTX, Inc. INDINAVIR-BASED CHEMICALLY DIMERIZING T-CELL ENGAGING COMPOSITIONS
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
CN113563474B (zh) * 2021-06-11 2023-05-02 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） EpCAM-CD16-NKG2D三特异性抗体及其应用
WO2024082269A1 (zh) * 2022-10-21 2024-04-25 武汉友芝友生物制药股份有限公司 双特异性抗体在免疫细胞治疗方面的应用
PE20260306A1 (es) 2023-06-12 2026-02-11 Amgen Inc Proteinas de union a receptor de linfotoxina beta agonistas
CN119409829B (zh) * 2024-11-15 2025-08-22 康元医疗科技(大连)有限公司 抗EpCAM纳米抗体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004533248A (ja) * 2001-05-03 2004-11-04 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 腫瘍特異的組換え抗体およびその使用
US7227002B1 (en) * 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
WO2008122551A2 (en) * 2007-04-04 2008-10-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anti-epcam antibody and uses thereof
JP2009511521A (ja) * 2005-10-11 2009-03-19 ミクロメット・アクチェンゲゼルシャフト 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
DE60038132T2 (de) 1999-12-27 2009-04-02 Crucell Holland B.V. Antikörper gegen Ep-Cam
DE10143106C1 (de) 2001-09-03 2002-10-10 Artus Ges Fuer Molekularbiolog Vermehrung von Ribonukleinsäuren
CN1812999A (zh) * 2003-05-31 2006-08-02 麦克罗梅特股份公司 包含EpCAM特异构建体的药物组合物
US8802442B2 (en) 2011-11-30 2014-08-12 Eric B. Wheeldon Apparatus and method for the remote sensing of blood in human feces and urine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227002B1 (en) * 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
JP2004533248A (ja) * 2001-05-03 2004-11-04 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 腫瘍特異的組換え抗体およびその使用
JP2009511521A (ja) * 2005-10-11 2009-03-19 ミクロメット・アクチェンゲゼルシャフト 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
WO2008122551A2 (en) * 2007-04-04 2008-10-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anti-epcam antibody and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5012014465; ＬＵＴＴＥＲＢＵＥＳＥ　ＰＥＴＲＡ: 'ＥＸＣＨＡＮＧＩＮＧ　ＨＵＭＡＮ　ＦＣgamma１　ＷＩＴＨ　ＭＵＲＩＮＥ　ＦＣgamma２Ａ　ＨＩＧＨＬＹ　ＰＯＴＥＮＴＩＡＴＥＳ　ＡＮＴＩ-ＴＵＭＯＲ　ＡＣＴＩＶＩＴＹ　以下備考' ＣＡＮＣＥＲ　ＩＭＭＵＮＯＬＯＧＹ　ＩＭＭＵＮＯＴＨＥＲＡＰＹ Ｖ５６　Ｎ４, 200704, Ｐ４５９-４６８ *
JPN5012014470; ＲＡＵＭ　Ｔ: 'ＡＮＴＩ-ＳＥＬＦ　ＡＮＴＩＢＯＤＩＥＳ　ＳＥＬＥＣＴＥＤ　ＦＲＯＭ　Ａ　ＨＵＭＡＮ　ＩＧＤ　ＨＥＡＶＹ　ＣＨＡＩＮ　ＲＥＰＥＲＴＯＩＲＥ：　Ａ　ＮＯＶＥＬ　ＡＰＰＲＯＡＣＨ　以下備考' ＣＡＮＣＥＲ　ＩＭＭＵＮＯＬＯＧＹ　ＡＮＤ　ＩＭＭＵＮＯＴＨＥＲＡＰＹ Ｖ５０　Ｎ３, 20010501, Ｐ１４１-１５０, ＳＰＲＩＮＧＥＲ-ＶＥＲＬＡＧ *
JPN6014042231; Ｂｒ．　Ｊ．　Ｃａｎｃｅｒ，　２００５，　９２（２），　ｐｐ．３４２-３４９ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510755A (ja) * 2013-03-06 2016-04-11 メリマック ファーマシューティカルズ インコーポレーティッド 抗Ｃ−ＭＥＴタンデムＦｃ二重特異性抗体
JP2020515262A (ja) * 2017-03-29 2020-05-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
JP7196094B2 (ja) 2017-03-29 2022-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
US11639394B2 (en) 2017-03-29 2023-05-02 Hoffmann-La Roche Inc. Bispecific antigen binding molecule for a costimulatory TNF receptor
JP2022506072A (ja) * 2018-10-26 2022-01-17 イミュノジェン， インコーポレイテッド ＥｐＣＡＭ抗体、活性化可能抗体、および免疫複合体、ならびにそれらの使用
JP7592009B2 (ja) 2018-10-26 2024-11-29 イミュノジェン， インコーポレイテッド ＥｐＣＡＭ抗体、活性化可能抗体、および免疫複合体、ならびにそれらの使用

Also Published As

Publication number Publication date
GB0909904D0 (en) 2009-07-22
EA201171463A1 (ru) 2012-07-30
US20100310463A1 (en) 2010-12-09
EP2440580A1 (en) 2012-04-18
US8637017B2 (en) 2014-01-28
WO2010142990A1 (en) 2010-12-16
CN102549017A (zh) 2012-07-04
BRPI1011005A2 (pt) 2018-03-06

Similar Documents

Publication Publication Date Title
US8637017B2 (en) Anti-EpCAM antibodies
US8822664B2 (en) Antibodies
US9353185B2 (en) Antibodies
AU2011340264B2 (en) Anti CCR4 antibodies and uses thereof
US20090070890A1 (en) Product
US10266599B2 (en) Antibodies which bind to the human CC chemokine receptor 4 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150609